Drug Type AAV based gene therapy |
Synonyms- |
Target |
Mechanism CAMK2A modulators(calcium/calmodulin dependent protein kinase II alpha modulators), Kv1.1 modulators(Voltage-gated potassium channel subunit Kv1.1 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Seizures | Preclinical | GB | 24 Jun 2024 |